Asset Details
Do you wish to reserve the book?
Dual-center retrospective cohort analysis of high-risk cutaneous squamous cell carcinoma tumors
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Dual-center retrospective cohort analysis of high-risk cutaneous squamous cell carcinoma tumors
Do you wish to request the book?
Dual-center retrospective cohort analysis of high-risk cutaneous squamous cell carcinoma tumors
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Dual-center retrospective cohort analysis of high-risk cutaneous squamous cell carcinoma tumors
2025
Overview
High-risk cutaneous squamous cell carcinoma (hr-cSCC) tumors exhibit aggressive behavior, leading to local recurrence, metastasis, and mortality. The management of hr-cSCC tumors is not well-defined. To clarify the impact of clinical risk factors and management strategies on disease-related outcomes (DROs) in patients with hr-cSCCs. This dual-center retrospective cohort study reviewed patient records from 2007 to 2023, focusing on hr-cSCC tumors classified as high-risk according to two staging systems. 160 adult patients with hr-cSCC were included. Tumors > 2 cm were associated with a higher risk of recurrence, metastasis, and mortality, with greater risk for tumors > 4 cm. Nonsurgical therapies were linked to higher recurrence and mortality rates compared to surgical monotherapy. Patients whose initial treatment was delayed > 60 days following biopsy had increased incidence of DROs. Other variables associated with at least one DRO included female sex, higher tumor grade, lymphovascular invasion, and advanced AJCC-8 stages. Limitations of this study include its retrospective design, narrow demographics, and variable follow-up times. This study identifies increased tumor diameter, non-surgical treatments, delayed treatment > 60 days after biopsy, female sex, tumor grade, lymphovascular invasion, and advanced tumor stage as significant risk factors for DROs in hr-cSCC. Importantly, our study provides new clarifying evidence that delayed surgical treatment of hr-cSCCs > 60 days after biopsy is associated with elevated incidence of DROs.
Publisher
Springer Berlin Heidelberg,Springer Nature B.V
Subject
/ Adult
/ Age
/ Aged
/ Biopsy
/ Carcinoma, Squamous Cell - mortality
/ Carcinoma, Squamous Cell - pathology
/ Carcinoma, Squamous Cell - therapy
/ Female
/ Humans
/ Male
/ Medicine
/ Neoplasm Recurrence, Local - epidemiology
/ Neoplasm Recurrence, Local - pathology
/ Oncology
/ Patients
/ Time-to-Treatment - statistics & numerical data
/ Tobacco
/ Tumors
